A Multicenter Phase 2 Trial to Evaluate Intracranial Response to Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Who Are Anti-PD1/PD-L1 Experienced

Conditions

Kidney | Melanoma, skin

Phase II

Volunteers
Health Professionals

What is the purpose of this trial?

This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma (RCC).

Find out more about who can participate in this trial

Trial with
Yale Cancer Center
Start Date
07/25/2022
End Date
06/01/2025

For more information about this study, contact:

Kira Fitzsimons Pavlik

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Harriet Kluger, MD
Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; Director, Yale SPORE in Skin Cancer, Yale Cancer Center; Vice Chair for Translational Research, Internal Medicine; Chief, Division of Skin and Kidney Cancer; Associate Cancer Center Director, Education, Training and Faculty Development; Deputy Section Chief, Medical Oncology

Sub-Investigators

Last Updated
07/26/2022
Study HIC
#2000030391

A Multicenter Phase 2 Trial to Evaluate Intracranial Response to Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Who Are Anti-PD1/PD-L1 Experienced

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information